Korsana Biosciences, Inc. KRSA
Regular-session close
After hours · Nov 20, 4:00 PM ET
- YTD
- +322.50%
- 1 year
- +277.87%
5D +6.77 (+21.02%)
- Market cap
- 1.71B
- EPS (ttm)
- -16.14
- Shares out
- 45.54M
- Forward P/E
- -10.71
- YTD return
- +322.50%
- 1-year return
- +277.87%
- 50-day average
- 32.19
- 200-day average
- 23.51
- Enterprise value
- 255.17M
- Total cash
- 134.16M
- Volume
- 265.24K
- Avg volume
- 115.71K
- Open
- 35.96
- Previous close
- 35.45
- Day's range
- 34.51 – 39.41
- 52-week range
- 7.56 – 44.66
- Beta
- 1.84
- Analysts
- Strong Buy
- Price target
- 44.00 (+17.1%)
- Earnings date
- Mar 29, 2027
Key statistics
- Total debt
- 1.10M
Fundamental scorecard
4 of 25 checks passed on KRSA’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 8.00
- Target (mean)
- 44.00
- Target (high)
- 70.00
- Strong buy0
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 29, 2027
Expected Mar 29, 2027. Consensus EPS estimate -0.83913.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 29, 2027 | Dec 30, 2026 | -0.89 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | -0.84695 | -3.19 | -2.34 | -276.65% |
| Aug 4, 2026 | Jun 30, 2026 | -3.45 | -0.41 | +3.04 | +88.12% |
| May 5, 2026 | Mar 31, 2026 | -2.66 | -2.66 | 0.00 | 0.00% |
| Mar 17, 2026 | Dec 31, 2025 | -2.66 | -1.75 | +0.91 | +34.21% |
| Nov 12, 2025 | Sep 30, 2025 | -121.80 | -0.30 | +121.50 | +99.75% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 13, 2026 | Wells Fargo | init | — | Overweight |
| Oct 5, 2026 | Wedbush | init | — | Outperform |
| Sep 28, 2026 | Guggenheim | init | — | Buy |
| Sep 14, 2026 | Stifel | init | — | Buy |
| Sep 14, 2026 | TD Cowen | init | — | Buy |
| Sep 11, 2026 | UBS | init | — | Buy |
About Korsana Biosciences, Inc.
Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases. The company has developed Therapeutic Targeting (THETA), a blood-brain barrier-penetrant shuttle platform designed to enhance central nervous system exposure of investigational therapies and enable delivery of large therapeutic molecules across the blood-brain barrier into the central nervous system. The company advances a pipeline of THETA-enabled therapeutics with an initial focus on neurodegenerative disorders. Its lead product candidate is KRSA-028, an anti-amyloid beta antibody for the treatment of Alzheimer's disease, which combines the THETA platform with elements of anti-amyloid beta approaches and targets a clinically relevant form of amyloid beta designed to improve brain uptake while reducing effects on reticulocytes. The company is also advancing a pipeline of additional THETA-enabled therapies for other neurodegenerative diseases. Korsana Biosciences, Inc. was incorporated in 2024 and is based in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- korsana.com
News
Your note
Sign in to keep a note on KRSA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHICKO RHONDA M. CPA | Chief Financial Officer | Conversion of Exercise of derivative security | Aug 13, 2026 | 25,018 |
| GRAUL REGINA MARGARET | Chief Executive Officer | Conversion of Exercise of derivative security | Aug 13, 2026 | 107,523 |
| HECHT PETER M | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jul 15, 2026 | 910,312 |
| HIGGINS MICHAEL J | Director | Stock Award(Grant) | Mar 24, 2025 | 30,740 |
| SLATE PATH CAPITAL LP | Beneficial Owner of more than 10% of a Class of Security | Sale | Nov 20, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fairmount Funds Management LLC | 19.99% | 9,103,729 | 341.94M | Sep 29, 2026 |
| TCG Crossover Management, LLC | 9.99% | 4,549,587 | 170.88M | Sep 29, 2026 |
| Venrock Adviser, LLC | 9.99% | 4,549,585 | 170.88M | Sep 29, 2026 |
| FMR, LLC | 7.03% | 3,201,135 | 120.23M | Sep 29, 2026 |
| JPMORGAN CHASE & CO | 5.90% | 2,687,943 | 100.96M | Sep 29, 2026 |
| FCPM III Services B.V. | 4.81% | 2,192,155 | 82.34M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.79% | 813,163 | 30.54M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 0.50% | 226,583 | 8.51M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 0.45% | 205,493 | 7.72M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 0.29% | 131,547 | 4.94M | Sep 29, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Health Care Fund | 0.14% | 65,364 | 2.46M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 0.11% | 51,518 | 1.94M | Sep 29, 2026 |
